SGO 2026 – GSK bucks the B7-H4 trend
The group impresses in ovarian and endometrial cancers.
Ideaya’s darovasertib plan comes together
Optimum-02 virtually replicates phase 1, and a filing will follow.
Oric gets a reality check
Rinzimetostat efficacy wanes further as the company moves into phase 3.
Allogene looks to consolidate its position
After a delay, the Alpha-3 study faces an April futility analysis.
Karyopharm gets an Xpovio blow
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
